Nanomedicine meets microRNA current advances in RNA-based nanotherapies for atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 9, 2016, Pages e73-e79

  Gadde, Suresh ^a   Rayner, Katey J ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Drug delivery system; MicroRNA; MicroRNA stability; Nanoparticle; Nanotechnology

Indexed keywords

COLLAGEN TYPE 4; DENDRIMER; LIPOSOME; LIVER X RECEPTOR; LOCKED NUCLEIC ACID; MESSENGER RNA; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 21; MICRORNA 33; NANOPARTICLE; PEPTIDE; POLYMER; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOPHYSICS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; INFLAMMATION; NANOMEDICINE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ANIMAL; GENETICS; MASS COMMUNICATION; RNA INTERFERENCE; RNAI THERAPEUTICS; TRENDS;

ANIMALS; ATHEROSCLEROSIS; DIFFUSION OF INNOVATION; HUMANS; MICRORNAS; NANOMEDICINE; NANOPARTICLES; RNA INTERFERENCE; RNAI THERAPEUTICS;

EID: 84983732527     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307481     Document Type: Article

References (87)

1. Vengrenyuk Y, Nishi H, Long X, Ouimet M, Savji N, Martinez FO, Cassella CP, Moore KJ, Ramsey SA, Miano JM, Fisher EA, Cholesterol loading reprograms the microRNA-143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. Arterioscler Thromb Vasc Biol 2015 35 535 546. doi: 10.1161/ATVBAHA.114.304029
2. Wang D, Deuse T, Stubbendorff M, Local MicroRNA Modulation Using a Novel Anti-miR-21-Eluting Stent Effectively Prevents Experimental In-Stent Restenosis. Arterioscler Thromb Vasc Biol 2015 35 1945 1953. doi: 10.1161/ATVBAHA.115.305597
3. Cao WJ, Rosenblat JD, Roth NC, Kuliszewski MA, Matkar PN, Rudenko D, Liao C, Lee PJ, Leong-Poi H, Therapeutic angiogenesis by ultrasound-mediated microRNA-126-3p delivery. Arterioscler Thromb Vasc Biol 2015 35 2401 2411. doi: 10.1161/ATVBAHA.115.306506
4. Canfrán-Duque A, Lin CS, Goedeke L, Suárez Y, Fernández-Hernando C, Micro-RNAs and high-density lipoprotein metabolism. Arterioscler Thromb Vasc Biol 2016 36 1076 1084. doi: 10.1161/ATVBAHA.116.307028
5. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, Leclercq IA, MacDougald OA, Bommer GT, Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010 285 33652 33661. doi: 10.1074/jbc.M110.152090
6. Marquart TJ, Allen RM, Ory DS, Baldán A, miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 2010 107 12228 12232. doi: 10.1073/pnas.1005191107
7. Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernández-Hernando C, MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010 328 1570 1573. doi: 10.1126/science.1189862
8. Tarling EJ, Ahn H, de Aguiar Vallim TQ, The nuclear receptor FXR uncouples the actions of miR-33 from SREBP-2. Arterioscler Thromb Vasc Biol 2015 35 787 795. doi: 10.1161/ATVBAHA.114.304179
9. Meiler S, Baumer Y, Toulmin E, Seng K, Boisvert WA, MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Arterioscler Thromb Vasc Biol 2015 35 323 331. doi: 10.1161/ATVBAHA.114.304878
10. Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M, Lu H, Fan D, MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2014 34 759 767. doi: 10.1161/ATVBAHA.113.302701
11. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Näär AM, MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010 328 1566 1569. doi: 10.1126/science.1189123
12. Allen RM, Marquart TJ, Albert CJ, Suchy FJ, Wang DQ, Ananthanarayanan M, Ford DA, Baldán A, miR-33 controls the expression of biliary transporters, and mediates statin-And diet-induced hepatotoxicity. EMBO Mol Med 2012 4 882 895. doi: 10.1002/emmm.201201228
13. Karunakaran D, Thrush AB, Nguyen MA, Macrophage Mitochondrial Energy Status Regulates Cholesterol Efflux and Is Enhanced by Anti-miR33 in Atherosclerosis. Circ Res 2015 117 266 278. doi: 10.1161/CIRCRESAHA.117.305624
14. Ramírez CM, Goedeke L, Rotllan N, Yoon JH, Cirera-Salinas D, Mattison JA, Suárez Y, de Cabo R, Gorospe M, Fernández-Hernando C, MicroRNA 33 regulates glucose metabolism. Mol Cell Biol 2013 33 2891 2902. doi: 10.1128/MCB.00016-13
15. Horie T, Baba O, Kuwabara Y, MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/-mice. J Am Heart Assoc 2012 1 e003376. doi: 10.1161/JAHA.112.003376
16. Ouimet M, Ediriweera HN, Gundra UM, MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J Clin Invest 2015 125 4334 4348. doi: 10.1172/JCI81676
17. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ, Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011 121 2921 2931. doi: 10.1172/JCI57275
18. Rotllan N, Ramírez CM, Aryal B, Esau CC, Fernández-Hernando C, Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/-mice-brief report. Arterioscler Thromb Vasc Biol 2013 33 1973 1977. doi: 10.1161/ATVBAHA.113.301732
19. Allen RM, Marquart TJ, Jesse JJ, Baldán A, Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33. Circ Res 2014 115 10 22. doi: 10.1161/CIRCRESAHA.115.303100
20. Goedeke L, Salerno A, Ramírez CM, Guo L, Allen RM, Yin X, Langley SR, Esau C, Wanschel A, Fisher EA, Suárez Y, Baldán A, Mayr M, Fernández-Hernando C, Long-Term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol Med 2014 6 1133 1141. doi: 10.15252/emmm.201404046
21. Horie T, Nishino T, Baba O, MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun 2013 4 2883. doi: 10.1038/ncomms3883
22. Karunakaran D, Richards L, Geoffrion M, Barrette D, Gotfrit RJ, Harper ME, Rayner KJ, Therapeutic inhibition of miR-33 promotes fatty acid oxidation but does not ameliorate metabolic dysfunction in diet-induced obesity. Arterioscler Thromb Vasc Biol 2015 35 2536 2543. doi: 10.1161/ATVBAHA.115.306404
23. Rayner KJ, Esau CC, Hussain FN, Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011 478 404 407. doi: 10.1038/nature10486
24. Krichevsky AM, Gabriely G, miR-21: A small multi-faceted RNA. J Cell Mol Med 2009 13 39 53. doi: 10.1111/j.1582-4934.2008.00556.x
25. Maegdefessel L, Azuma J, Toh R, Deng A, Merk DR, Raiesdana A, Leeper NJ, Raaz U, Schoelmerich AM, McConnell MV, Dalman RL, Spin JM, Tsao PS, MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-Augmented expansion. Sci Transl Med 2012 4 122ra22. doi: 10.1126/scitranslmed.3003441
26. Wang M, Li W, Chang GQ, Ye CS, Ou JS, Li XX, Liu Y, Cheang TY, Huang XL, Wang SM, MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol 2011 31 2044 2053. doi: 10.1161/ATVBAHA.111.229559
27. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C, MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007 100 1579 1588. doi: 10.1161/CIRCRESAHA.106.141986
28. McDonald RA, White KM, Wu J, Cooley BC, Robertson KE, Halliday CA, McClure JD, Francis S, Lu R, Kennedy S, George SJ, Wan S, van Rooij E, Baker AH, miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. Eur Heart J 2013 34 1636 1643. doi: 10.1093/eurheartj/eht105
29. Zhang A, Liu Y, Shen Y, Xu Y, Li X, miR-21 modulates cell apoptosis by targeting multiple genes in renal cell carcinoma. Urology 2011 78 474.e13 474.e19. doi: 10.1016/j.urology.2011.03.030
30. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G, The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: Correlates with human disease. Cell Death Differ 2009 16 1590 1598. doi: 10.1038/cdd.2009.153
31. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D, miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009 460 705 710. doi: 10.1038/nature08195
32. Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S, Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012 14 249 256. doi: 10.1038/ncb2441
33. -/- mice. Thromb Haemost 2014 112 796 802. doi: 10.1160/TH13-11-0905
34. Kent OA, McCall MN, Cornish TC, Halushka MK, Lessons from miR-143/145: The importance of cell-Type localization of miRNAs. Nucleic Acids Res 2014 42 7528 7538. doi: 10.1093/nar/gku461
35. Karunakaran D, Rayner KJ, Macrophage mirnas in atherosclerosis. Biochimica et Biophysica Acta 2016. doi: 10.1016/j.bbalip.2016.02.006
36. Heymans S, Corsten MF, Verhesen W, Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013 128 1420 1432. doi: 10.1161/CIRCULATIONAHA.112.001357
37. Wei Y, Zhu M, Corbalán-Campos J, Heyll K, Weber C, Schober A, Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of microRNA-155 on atherosclerosis. Arterioscler Thromb Vasc Biol 2015 35 796 803. doi: 10.1161/ATVBAHA.114.304723
38. Donners MM, Wolfs IM, Stöger LJ, van der Vorst EP, Pöttgens CC, Heymans S, Schroen B, Gijbels MJ, de Winther MP, Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One 2012 7 e35877. doi: 10.1371/journal.pone.0035877
39. Pankratz F, Bemtgen X, Zeiser R, Leonhard F, Kreuzaler S, Hilgendorf I, Smolka C, Helbing T, Hoefer I, Esser JS, Kustermann M, Moser M, Bode C, Grundmann S, MicroRNA-155 exerts cell-specific anti-Angiogenic but pro-Arteriogenic effects during adaptive neovascularization. Circulation 2015 131 1575 1589. doi: 10.1161/CIRCULATIONAHA.114.014579
40. Rayner KJ, MicroRNA-155 in the heart: The right time at the right place in the right cell. Circulation 2015 131 1533 1535. doi: 10.1161/CIRCULATIONAHA.115.016327
41. Li K, Ching D, Luk FS, Raffai RL, Apolipoprotein E enhances microRNA-146a in monocytes and macrophages to suppress nuclear factor-κB-driven inflammation and atherosclerosis. Circ Res 2015 117 e1 e11. doi: 10.1161/CIRCRESAHA.117.305844
42. Davis S, Lollo B, Freier S, Esau C, Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006 34 2294 2304. doi: 10.1093/nar/gkl183
43. Gandellini P, Profumo V, Folini M, Zaffaroni N, MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets 2011 15 265 279. doi: 10.1517/14728222.2011.550878
44. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, Hansen HF, Koch T, Pappin D, Hannon GJ, Kauppinen S, Silencing of microRNA families by seed-Targeting tiny LNAs. Nat Genet 2011 43 371 378. doi: 10.1038/ng.786
45. Broderick JA, Zamore PD, MicroRNA therapeutics. Gene Ther 2011 18 1104 1110. doi: 10.1038/gt.2011.50
46. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW, Weinberg RA, Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010 28 341 347. doi: 10.1038/nbt.1618
47. Bangham AD, Liposomes: The Babraham connection. Chem Phys Lipids 1993 64 275 285
48. Torchilin VP, Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005 4 145 160. doi: 10.1038/nrd1632
49. Gabizon A, Shmeeda H, Barenholz Y, Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 2003 42 419 436. doi: 10.2165/00003088-200342050-00002
50. Gadde S, Multi-drug delivery nanocarriers for combination therapy. MedChemComm 2015 6 1916 1929
51. Pridgen EM, Langer R, Farokhzad OC, Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond) 2007 2 669 680. doi: 10.2217/17435889.2.5.669
52. Kamaly N, Fredman G, Subramanian M, Gadde S, Pesic A, Cheung L, Fayad ZA, Langer R, Tabas I, Farokhzad OC, Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A 2013 110 6506 6511
53. Miller MA, Zheng YR, Gadde S, Pfirschke C, Zope H, Engblom C, Kohler RH, Iwamoto Y, Yang KS, Askevold B, Kolishetti N, Pittet M, Lippard SJ, Farokhzad OC, Weissleder R, Tumour-Associated macrophages act as a slow-release reservoir of nano-Therapeutic Pt(IV) pro-drug. Nat Commun 2015 6 8692. doi: 10.1038/ncomms9692
54. Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW, Bander NH, Lippard SJ, Langer R, Karnik R, Farokhzad OC, Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond) 2013 8 687 698. doi: 10.2217/nnm.12.134
55. Wang Y-J, Larsson M, Huang W-T, Chiou S-H, Nicholls SJ, Chao J-I, Liu D-M, The use of polymer-based nanoparticles and nanostructured materials in treatment and diagnosis of cardiovascular diseases: Recent advances and emerging designs. Prog Polym Sci 2016 57 153 178
56. Veiseh O, Tang BC, Whitehead KA, Anderson DG, Langer R, Managing diabetes with nanomedicine: Challenges and opportunities. Nat Rev Drug Discov 2015 14 45 57. doi: 10.1038/nrd4477
57. Puppi D, Chiellini F, Piras AM, Chiellini E, Polymeric materials for bone and cartilage repair. Prog Polym Sci 2010 35 403 440
58. Stary G, Olive A, Radovic-Moreno AF, A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science 2015 348 aaa8205. doi: 10.1126/science.aaa8205
59. Fraser CC, Altreuter DH, Ilyinskii P, Pittet L, LaMothe RA, Keegan M, Johnston L, Kishimoto TK, Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates. Vaccine 2014 32 2896 2903. doi: 10.1016/j.vaccine.2014.02.024
60. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC, Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev 2012 41 2656 2672. doi: 10.1039/c2cs15261d
61. Caminade A-M, Turrin C-O, Dendrimers for drug delivery. J Mater Chem B 2014 2 4055 4066
62. Thaxton CS, Rink JS, Naha PC, Cormode DP, Lipoproteins and lipoprotein mimetics for imaging and drug delivery. Adv Drug Delivery Rev 2016. doi: 10.1016/j.addr.2016.04.020
63. He Q, Gao Y, Zhang L, Zhang Z, Gao F, Ji X, Li Y, Shi J, A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011 32 7711 7720. doi: 10.1016/j.biomaterials.2011.06.066
64. Jaffer FA, Libby P, Weissleder R, Optical and multimodality molecular imaging: Insights into atherosclerosis. Arterioscler Thromb Vasc Biol 2009 29 1017 1024. doi: 10.1161/ATVBAHA.108.165530
65. Miao W, Shim G, Lee S, Lee S, Choe YS, Oh YK, Safety and tumor tissue accumulation of pegylated graphene oxide nanosheets for co-delivery of anticancer drug and photosensitizer. Biomaterials 2013 34 3402 3410. doi: 10.1016/j.biomaterials.2013.01.010
66. Goenka S, Sant V, Sant S, Graphene-based nanomaterials for drug delivery and tissue engineering. J Control Release 2014 173 75 88. doi: 10.1016/j.jconrel.2013.10.017
67. Bitounis D, Ali-Boucetta H, Hong BH, Min DH, Kostarelos K, Prospects and challenges of graphene in biomedical applications. Adv Mater 2013 25 2258 2268. doi: 10.1002/adma.201203700
68. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC, Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev 2012 41 2971 3010. doi: 10.1039/c2cs15344k
69. Kamaly N, Fredman G, Fojas JJ, Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 2016 10 5280 5292. doi: 10.1021/acsnano.6b01114
70. Carthew RW, Sontheimer EJ, Origins and Mechanisms of miRNAs and siRNAs. Cell 2009 136 642 655. doi: 10.1016/j.cell.2009.01.035
71. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Löffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J, A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006 13 1222 1234. doi: 10.1038/sj.gt.3302777
72. Kim D, Hong J, Moon HH, Nam HY, Mok H, Jeong JH, Kim SW, Choi D, Kim SH, Anti-Apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: Use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier. J Control Release 2013 168 125 134. doi: 10.1016/j.jconrel.2013.02.031
73. Somasuntharam I, Boopathy AV, Khan RS, Martinez MD, Brown ME, Murthy N, Davis ME, Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials 2013 34 7790 7798. doi: 10.1016/j.biomaterials.2013.06.051
74. Leuschner F, Dutta P, Gorbatov R, Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011 29 1005 1010. doi: 10.1038/nbt.1989
75. Sager HB, Dutta P, Dahlman JE, RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med 2016 8 342ra80. doi: 10.1126/scitranslmed.aaf1435
76. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC, Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014 66 2 25. doi: 10.1016/j.addr.2013.11.009
77. Miller MA, Gadde S, Pfirschke C, Engblom C, Sprachman MM, Kohler RH, Yang KS, Laughney AM, Wojtkiewicz G, Kamaly N, Bhonagiri S, Pittet MJ, Farokhzad OC, Weissleder R, Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci Transl Med 2015 7 314ra183. doi: 10.1126/scitranslmed.aac6522
78. Nahrendorf M, Keliher E, Marinelli B, Leuschner F, Robbins CS, Gerszten RE, Pittet MJ, Swirski FK, Weissleder R, Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Thromb Vasc Biol 2011 31 750 757. doi: 10.1161/ATVBAHA.110.221499
79. Mulder WJ, Fayad ZA, Nanomedicine captures cardiovascular disease. Arterioscler Thromb Vasc Biol 2008 28 801 802. doi: 10.1161/ATVBAHA.108.165332
80. Gadde S, Even-Or O, Kamaly N, Hasija A, Gagnon PG, Adusumilli KH, Erakovic A, Pal AK, Zhang XQ, Kolishetti N, Shi J, Fisher EA, Farokhzad OC, Development of therapeutic polymeric nanoparticles for the resolution of inflammation. Adv Healthc Mater 2014 3 1448 1456. doi: 10.1002/adhm.201300688
81. Zhang XQ, Even-Or O, Xu X, van Rosmalen M, Lim L, Gadde S, Farokhzad OC, Fisher EA, Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Adv Healthc Mater 2015 4 228 236. doi: 10.1002/adhm.201400337
82. -/- mice. Arterioscler Thromb Vasc Biol 2016 36 491 500. doi: 10.1161/ATVBAHA.115.307057
83. Fredman G, Kamaly N, Spolitu S, Milton J, Ghorpade D, Chiasson R, Kuriakose G, Perretti M, Farokhzad O, Farokzhad O, Tabas I, Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 2015 7 275ra20. doi: 10.1126/scitranslmed.aaa1065
84. La Rocca G, Olejniczak SH, Gonzalez AJ, Briskin D, Vidigal JA, Spraggon L, DeMatteo RG, Radler MR, Lindsten T, Ventura A, Tuschl T, Leslie CS, Thompson CB, In vivo, argonaute-bound micrornas exist predominantly in a reservoir of low molecular weight complexes not associated with mRNA. Proc Natl Acad Sci U S A 2015 112 767 772
85. Segers FM, den Adel B, Bot I, van der Graaf LM, van der Veer EP, Gonzalez W, Raynal I, de Winther M, Wodzig WK, Poelmann RE, van Berkel TJ, van der Weerd L, Biessen EA, Scavenger receptor-AI-Targeted iron oxide nanoparticles for in vivo MRI detection of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2013 33 1812 1819. doi: 10.1161/ATVBAHA.112.300707
86. Cyrus T, Zhang H, Allen JS, Williams TA, Hu G, Caruthers SD, Wickline SA, Lanza GM, Intramural delivery of rapamycin with alphavbeta3-Targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol 2008 28 820 826. doi: 10.1161/ATVBAHA.107.156281
87. Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M, Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci 2010 31 199 205. doi: 10.1016/j.tips.2010.01.003